Key secondary outcomes were changes from baseline in HAM-A total scores for the 2.5 and 10mg dose , Hospital Anxiety and Depression anxiety subscore , 36-Item Short-Form Health Survey , Sheehan Disability Scale , and Clinical Global Impression-Improvement Scale score , as well as HAM-A response rate at week 8 .